Niacinate
80/100
This product is generally safe
- Niacin: 505mg is 14.4× the Tolerable Upper Intake Level (35mg)
- 100% of ingredients have research evidence
C
Label Compliance Grade
Product Label
Have a supplement label? Find it here.
Upload a photo of any supplement label to search our database of 92,312 products.
Safety Alerts
⚠️ Niacin: 505mg is 14.4× the Tolerable Upper Intake Level (35mg)
Label Data
1 Tablet(s)
Serving Size
90
Servings
Other Combinations
Product Type
100%
Evidence Coverage
Supplement Facts — Evidence Check
505 mg
(3156% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 14.4× (UL: 35 mg)
📚 193 studies (Tier A: 5, B: 63)
115 mg
📊 Market median: 550.0mg (217 products)
📚 29 studies (Tier A: 0, B: 5)
Other Ingredients
Microcrystalline Cellulose
Dicalcium Phosphate
Coating
Stearic Acid
Croscarmellose Sodium
Silica
Vegetable Stearate
Label Claims — Verification
❓
All Other
❓
Structure/Function
All Other (97% of products)
Structure/Function (86% of products)
Nutrient (36% of products)
Target Groups
Adult (18 - 50 Years)
Gluten Free
Product Information
📋 Directions for Use
Suggested Usage: As a dietary supplement, adults take 1 tablet daily, or as directed by your health professional.
⚠️ Warnings & Precautions
Warning: If you are pregnant, nursing, have any health condition or taking any medication, consult your health professional before using this product.
Keep out of the reach of children.
Use only if safety seal is intact.
🧪 Formulation Notes
Gluten-free, non-GMO
Additional Information
Store in a cool, dry place.
Scan to learn about our manufacturing excellence Contents may not fill package in order to accommodate required labeling. Please rely on stated quantity.
Product Details
UPC / SKU
7 45287 02012 8
DSLD Entry Date
2022-04-11
Product Type
Other Combinations
Form
Tablet or Pill
Brand
Douglas Laboratories
DSLD ID
261494
Data Updated
2026-04-11
Research Evidence
241
Research Sources
55
Avg Quality Score
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
A
Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
A
A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
A
Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
B
Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Compare Similar Products
Rezistaf
LifeLink
100
Coenzymated B-3 25 mg
Source Naturals
100
Vitamin B Complex
Simply Supplements
100
Test X180 Boost
Force Factor
100
8-Hour Alert
MHP Maximum Human Performance
100